3.24

0.92% -0.03

After Hours: 3.22 -0.02 -0.62%

Dare Bioscience Inc (DARE)

Overview News Price History Financials Discussions Forecast Stock Split

Dare Bioscience Inc stock is traded at $3.24, with a volume of 25,138. It is down -0.92% in the last 24 hours and down -9.50% over the past month. Dare Bioscience Inc is a biopharmaceutical company committed to advancing innovative products for women's health. The company identifies, develops and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in advanced clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.

Previous Close:

$3.27

Open:

$3.23

24h Volume:

25,138

Relative Volume:

0.22

Market Cap:

$27.52M

Revenue:

Net Income/Loss:

$-30.16M

P/E Ratio:

-7.0435

EPS:

-0.46

Net Cash Flow:

$-39.49M

1W Performance:

-1.22%

1M Performance:

-9.50%

6M Performance:

+560.95%

1Y Performance:

+601.60%

1-Day Range:

$3.22

$3.3099

1-Week Range:

$3.22

$3.3618

52-Week Range:

$0.27

$4.25

Dare Bioscience Inc Stock (DARE) Company Profile

Name

Dare Bioscience Inc

Sector

Healthcare (1190)

Industry

Biotechnology (681)

Phone

858-926-7655

Address

3655 NOBEL DRIVE, SAN DIEGO, CA

Employee

Twitter

@DareBioscience

Next Earnings Date

2024-08-12

Latest SEC Filings

DARE's Discussions on Twitter

Dare Bioscience Inc Stock (DARE) Latest News

Sep 24, 2024

Dye & Durham Limited - Baystreet.ca

Sep 24, 2024

Sep 23, 2024

DADA’s 2023 Market Dance: Down -64.46% – Time to Invest? - The InvestChronicle

Sep 23, 2024

Sep 22, 2024

Barrow Hanley Mewhinney & Strauss LLC Raises Stake in Darling Ingredients Inc. (NYSE:DAR) - Defense World

Sep 22, 2024

Darling Ingredients Inc. (NYSE:DAR) Shares Sold by Meiji Yasuda Asset Management Co Ltd. - Defense World

Sep 22, 2024

Sep 21, 2024

MDA Space shares target raised on Telesat Lightspeed deals By Investing.com - Investing.com Australia

Sep 21, 2024

Sep 19, 2024

Daré Bioscience (NASDAQ:DARE) Share Price Crosses Below Two Hundred Day Moving Average of $4.51 - Defense World

Sep 14, 2024

Sep 06, 2024

Daré Bioscience (NASDAQ:DARE) Stock Price Passes Below Two Hundred Day Moving Average of $4.59 - Defense World

Sep 06, 2024

Sep 02, 2024

Its Stock Has Paid Off Big Time For Dare Bioscience Inc - SETE News

Sep 02, 2024

Aug 26, 2024

Daré Bioscience Announces Publication in The Journal of - GlobeNewswire

Aug 26, 2024

Sildenafil cream shows promise for FSAD without common side effects - Investing.com

Aug 26, 2024

Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Safety Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6% - StockTitan

Aug 26, 2024

Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Safety Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6% - Yahoo Finance

Aug 26, 2024

Aug 24, 2024

Daré Bioscience (NASDAQ:DARE) Shares Pass Below Two Hundred Day Moving Average of $4.62 - Defense World

Aug 24, 2024

Aug 17, 2024

Daré Bioscience, Inc. (NASDAQ:DARE) to Post FY2024 Earnings of ($0.33) Per Share, Brookline Capital Management Forecasts - Defense World

Aug 17, 2024

Aug 16, 2024

HC Wainwright Comments on Daré Bioscience, Inc.’s Q3 2024 Earnings (NASDAQ:DARE) - Defense World

Aug 16, 2024

Maxim Group Reiterates “Hold” Rating for Daré Bioscience (NASDAQ:DARE) - Defense World

Aug 16, 2024

Aug 14, 2024

Sildenafil Cream study suggests simplified patient reporting - Investing.com

Aug 14, 2024

Aug 13, 2024

Sildenafil Cream study suggests simplified patient reporting By Investing.com - Investing.com Canada

Aug 13, 2024